GRAL ALERT: Investigation Launched into GRAIL, Inc., RGRD Law Attorneys Encourage Investors and Potential Witnesses to Contact Law Firm

Company Overview - GRAIL, Inc. is a commercial-stage healthcare company focused on providing multi-cancer early detection testing and services [2]. Investigation Announcement - Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving GRAIL, Inc. [1]. Trial Results - On February 19, 2026, GRAIL announced results from its NHS-Galleri trial, which assessed annual multi-cancer screening using the Galleri test. The trial did not meet its primary endpoint, as a statistically significant reduction in Stage III-IV cancer was not observed [3]. Stock Market Reaction - Following the announcement of the trial results, GRAIL's stock price experienced a significant decline [3].